|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
Bolero-2 |
Bösartige Neubildung der Brustdrüse [Mamma]
[C50.-]
|
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole
|
 |
 |
|
BrainMet |
Sonstige Tumore
[]
|
Brain Metastases in Breast Cancer Network Germany (BMBC)
Meeting a clinical need for the improvement of patient outcome
|
 |
|
|
|
BRENDA |
Sonstige und nicht näher bezeichnete Typen des Non-Hodgkin-Lymphoms
[C85.-]
|
Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients („Slow Go“) with Aggressive CD20-positive B-cell Lymphoma
(Diffus großzellige B-Zell-Lyphom, Lymphozyten, B-Lymphozyten, Lymphom, follikuläres Lymphom, Mantelzell-Lyphom, Non-Hodgkin-Lymphom)
|
|
|
|
|
BRF117277 GlaxoSmithKline |
Bösartiges Melanom der Haut, nicht näher bezeichnet
[C43.9]
|
A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain
|
 |
|
|
|
BUU-2/EEA |
Üsophagitis
[K20]
|
BUU-2/EEA,Behandlung mit Budesinide effervescent tbl. Vs.viscous Budesonide suspension vs.placebo bei eosinophilic esophagitis
|
|
|
|
|
C-144-01 (TIL) |
Krebserkrankungen der Haut
[]
|
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
Z-Nummer: 362 - CAVE: Screening nur nach OK von Sponsor!
|
|
|
|
|
C25608/4027/BP/EU |
Sonstige Studien
[-]
|
A european mullticenter, open-label study of breakthrough cancer pain: Assessment of Fentanyl buccal tablets titration and treatment in opioid-treatment patients
|
|
|
|
|
CA013-004 |
Sonst. urogenitale Tumore z.B. Blase,Niere
[]
Prostatakrebs
[]
Krebserkrankungen der Haut
[]
Lungenkrebs
[]
Sonstige Tumore
[]
Bauchspeicheldrüsenkrebs (Pankreas)
[]
|
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors - CAVE!! keine Rekrutierung mehr in Melanom-, NSCLC- und CRPC-Kohorte!!! SCCHN Kohorte ab 31. Oktober 2019 auch geschlossen; weiterhin offen: RCC
Z.Nummer: 336
|
|
|
|
|
CA017-078 |
Sonst. urogenitale Tumore z.B. Blase,Niere
[]
|
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
|
|
|
|
|
CA204 008 |
Multiples Myelom
[C90.0-]
|
PROSPECTIVE RESEARCH ASSESSMENT IN MULTIPLE MYELOMA: AN OBSERVATIONAL EVALUATION (PREAMBLE)
|
 |
|
|
|
CA204004 |
Multiples Myelom
[C90.0-]
|
Relapsed refractory (1-4 prior therapy lines) Multiple Myeloma Intravenous investigational monoclonal antibody with a plasma-cell specific target ELOTUZUMAB. The study drug will be administered weekly for the first two cycles, and starting in cycle 3 every 2 weeks within each 28 day treatment cycle
|
|
|
|
|
CA204006 |
Multiples Myelom
[C90.0-]
|
A Phase III, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Withoud Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
|
|
|
|
|
CA209-037 |
Krebserkrankungen der Haut
[]
Krebserkrankungen der Haut
[]
|
A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
|
|
|
|
|
CA209-577 |
Speiseröhrenkrebs
[]
|
Ende der Rekrutierung!
A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer
Z.:335
|
|
|
|
|
CA209-649 |
Magentumor
[]
|
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Z-Nummer: 320
|
|
|
|
|
CA209-651 |
Kopf-Hals-Tumore
[C00-C14, C30.-,C33]
|
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab+cisplatin/carboplatin+ floururacil) as First Line Therapy in Recurrent or Metastastic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Z-Nr.: Z316
|
|
|
|
|
CA209-76K |
Bösartiges Melanom der Haut, nicht näher bezeichnet
[C43.9]
|
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab
versus Placebo after Complete Resection of Stage IIB/C Melanoma
|
|
|
|
|
CA209-9DX |
Leberzellkarzinom
[C22.0]
|
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CheckMate 9DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9DX)
|
|
|
|
|
CA209214 |
Sonstige Tumore
[]
|
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic RenalCell Carcinoma
|
|
|
|
|
CA209274 |
Sonstige Tumore
[]
|
a Phase III, randomized, double-blind, multicenter study of adjuvant Nivolumab versus Placebo in subjects with high risc invasive urothel carcinoma
|
|
|
|
|
CA209275 |
Sonstige Tumore
[]
|
A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent
|
|
|
|
|
CA224-047 |
Krebserkrankungen der Haut
[]
|
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Z:339
|
|
|
|
|
Cabozantinib |
Prostatakrebs
[]
|
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
|
|
|
|
|
CAIN457A2303 |
Psoriasis, nicht näher bezeichnet
[L40.9]
|
A randomized, double-blind, placebo controlled, multicenter study of subcutaneous AIN457 to demonstrate efficacy at Week 12 compared to placebo and etanercept and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis.
|
|
|
|
|
CAIN457ADE01T (Secukinomab) |
Pyoderma gangraenosum
[L88]
|
Pilotstudie zum Einsatz von anti-IL-17 (Secukinumab) bei der Behandlung von Pyoderma gangraenosum CAIN457ADE01T
|
|
|
